CONSULTING AGREEMENTConsulting Agreement • March 14th, 2012 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS CONSULTING AGREEMENT (the “Agreement”), made this 1st day of January, 2011 (“Effective Date”) is entered into by Idera Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 167 Sidney Street, Cambridge, MA 02139 (the “Company”), and Karr Pharma Consulting, LLC, having a place of business located at 707 Dominion Drive, St. Louis, Missouri 63131 (the “Consultant”). Company and Consultant may be referred to herein individually as a “Party” and collectively as the “Parties.”
TERMINATION AGREEMENT Dated November 30, 2011 By and Between Idera Pharmaceuticals, Inc. And Merck KGaA concerning the “License Agreement between Idera Pharmaceuticals, Inc. and Merck KGaA” dated December 18, 2007 as amendedTermination Agreement • March 14th, 2012 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • England
THIS TERMINATION AGREEMENT (the “Agreement”) is dated as of November 30, 2011 (the “Effective Date”) by and between Idera Pharmaceuticals, Inc., a corporation organized under the laws of Delaware having its place of business at 167 Sidney Street, Cambridge, MA 02139, United States (“Idera”) and Merck KGaA, a general partnership limited by shares organized under German law having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany (“Merck”). Idera and Merck may be referred to herein as a “Party” or, collectively, as “Parties”.
December 2, 2011Idera Pharmaceuticals, Inc. • March 14th, 2012 • Biological products, (no disgnostic substances) • Massachusetts
This letter amends and restates the employment letter dated August 1, 2011 between you and Idera Pharmaceuticals, Inc. (the “Company”), as amended (the “Prior Agreement”). Effective upon the date of this Agreement (the “Effective Date”), your continued employment with the Company shall be on the terms set forth in this Agreement and the Prior Agreement shall be terminated and of no further force or effect.
AMENDMENT TO THE CONSULTING AGREEMENTThe Consulting Agreement • March 14th, 2012 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Amendment, effective the 31st day of December, 2010, (“Amendment Date”) is by and between IDERA PHARMACEUTICALS, INC., a Delaware corporation, having a place of business at 167 Sidney Street, Cambridge, Massachusetts 02139 (hereinafter referred to as “Idera”) and MALCOLM MACCOSS, PH.D., an individual being a Member of Bohicket Pharma Consulting LLC and having a place of residence located 2556 Seabrook Island Road, Seabrook Island, South Carolina 29455 (hereinafter referred to as the “Consultant”). Idera and Consultant may be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO THE CONSULTING SERVICES AGREEMENTThe Consulting Services Agreement • March 14th, 2012 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Amendment, effective the 19 day of December, 2011, (“Amendment Date”) is by and between IDERA PHARMACEUTICALS, INC., having an place of business at 167 Sidney Street, Cambridge, Massachusetts 02139 (hereinafter referred to as “Idera”) and KARR PHARMA CONSULTING, LLC, having a place of business at 707 Dominion Drive, St. Louis, Missouri 63131 (hereinafter referred to as the “Consultant”). Idera and Consultant may be referred to herein individually as a “Party” and collectively as the “Parties.”
